Clinical Trials
34 trialsNCT00217737 2026-05-29
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04068610 2026-05-15
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
Phase 1/2 Active not recruiting
NCT05983367 2026-02-20
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Inspirna, Inc.
Phase 2 Terminated
NCT04109924 2026-02-10
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Phase 2 Completed
NCT00826540 2026-01-20
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT02138617 2025-05-18
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT00321828 2024-03-21
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
NSABP Foundation Inc
Phase 2 Completed
NCT00098787 2023-07-05
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT00467142 2022-11-01
OMEGA
Institut Bergonié
Phase 2 Completed
NCT00193219 2022-01-11
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00314353 2021-10-06
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
NSABP Foundation Inc
Phase 2 Terminated
NCT00932438 2021-06-11
DEBIRI
University of Louisville
Phase 1/2 Completed
NCT01280643 2021-03-15
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Fox Chase Cancer Center
Phase NA Terminated
NCT00265850 2020-05-07
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00096278 2019-07-30
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02305758 2018-11-20
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
AbbVie
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT01279681 2017-12-08
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00449163 2017-05-11
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
University of Miami
Phase 2 Terminated
NCT00127036 2017-03-23
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01322815 2016-08-15
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
Georgetown University
Phase 2 Terminated
NCT01320683 2016-07-19
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT00100841 2015-07-27
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00826800 2015-04-15
Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Terminated
NCT00416494 2014-09-03
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Duke University
Phase 2 Completed
NCT00499369 2014-07-31
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
National Cancer Institute (NCI)
Phase 3 Terminated
NCT01198548 2014-07-21
High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00107315 2014-07-04
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00112918 2013-08-27
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00290615 2013-05-07
Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Duke University
Phase 2 Completed